InflaRx (IFRX) Debt Ratio (2020 - 2026)

InflaRx (IFRX) posted Debt Ratio of 0.06 for Q2 2025, up 4705.05% sequentially from 0.0 in Q3 2022.

InflaRx (IFRX) Debt Ratio (2020 - 2026) Analysis & Trends

InflaRx has reported Debt Ratio for 4 years, with the latest figure at 0.06 in Q2 2025.

Quarterly Debt Ratio changed N/A year-over-year to 0.06 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 0.06 (changed N/A YoY) and the FY2021 annual result came in at 0.0, down 17.24% from the prior year.
Debt Ratio improved to 0.06 in Q2 2025 per IFRX's latest filing, from 0.0 in the prior quarter.
Over five years, Debt Ratio peaked at 0.06 in Q2 2025 and troughed at 0.0 in Q2 2021.
A 3-year average of 0.01 and a median of 0.0 in 2022 frame the typical range for Debt Ratio.
The widest YoY moves for Debt Ratio: up 22.84% in 2022, down 53.08% in 2022.
Over 3 years, Debt Ratio stood at 0.0 in 2021, then gained by 16.74% to 0.0 in 2022, then surged by 4705.05% to 0.06 in 2025.
According to Business Quant data, Debt Ratio over the past three periods registered 0.06, 0.0, and 0.0 for Q2 2025, Q3 2022, and Q2 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.71 Bn	131.86 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.87 Bn	78.87 Bn	3.93 Bn	0.05
3	Argenx Se	65.40 Bn	60.22 Bn	1.37 Bn	-
4	Moderna	59.36 Bn	54.22 Bn	52.00 Mn	0.05
5	BeOne Medicines	42.12 Bn	37.02 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.91 Bn	28.60 Bn	992.69 Mn	-
7	BioNTech SE	28.17 Bn	9.78 Bn	668.28 Mn	0.03
8	Insmed	27.58 Bn	26.42 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	0.47
10	InflaRx	142.65 Mn	-41.60 Mn	2.74 Bn	-

Download Data